Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kokubunnji-Shi, Japan Clinical Trials

A listing of Kokubunnji-Shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

This phase I trial will involve 6 patients suffering from chronic ischemic cardiomyopathy and congestive heart failure, to be compared with historical control subjects. This study will be conducted as a collaborative project between the Sakakibara Heart Institute and the CellBank of Japan. The trial is designed to assess the ...

Phase

4.25 miles

Learn More »

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

Phase

4.86 miles

Learn More »

Study Assessing the Safety Tolerability and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

This is an ascending multiple oral dose, open-label study assessing the safety, tolerability, and pharmacokinetics of SEP-363856 in male and female subjects with schizophrenia. Subjects will have up to two visits, including a screening visit, and a 17-day in-clinic period. Eligible subjects will be admitted to the clinic on Day ...

Phase

7.9 miles

Learn More »

Safety Tolerability and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

The trial is conducted in Asia, Europe and North America. The aim of the study is to evaluate the safety of administration under the skin of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A.

Phase

8.01 miles

Learn More »

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design. Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 ...

Phase

9.0 miles

Learn More »